In Russia, analogues of Ozempik have surpassed the original in sales to a record high
In Russia, sales of drugs based on semaglutide, known under the brand name Ozempic, have increased several-fold.
Sales of analogues of the Ozempic brand, which has left the Russian Federation, have surpassed the original to a record high.
This is associated with the emergence of analogues of the drug, which Russians use not for diabetes, but for weight loss, writes RBC .
According to the analytical company DSM Group, 829.9 thousand packages of drugs with the international non-proprietary name semaglutide were sold in Russia in the first eight months of 2024.
For comparison, for the same period last year, these sales amounted to 206.8 thousand packages.
After the cessation of deliveries of Ozempic in Russia, analogues of the original drug appeared from local pharmaceutical companies.
The generic drug Semavik from Geropharm and the drug Quincenta from Promomed accounted for the bulk of semaglutide sales in 2024.
